araag2/HINT huggingface dataset:
Clinical trial NCT01009047 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone extended release (er), aripiprazole
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must currently meet the Diagnostic and Statistical Manual of Mental
             Disorders Fourth Edition (DSM-IV) criteria for schizophrenia and have experienced
             symptoms of the illness for at least 1 year, and they should have had at least
             treatment with 1 antipsychotic before participation in this study

          -  Participants having a Positive and Negative Syndromes Scale (PANSS) score between 60
             and 120 inclusive at Screening

          -  Female participants must be incapable of pregnancy, or if heterosexually active and
             capable of pregnancy, have been using an acceptable method of contraception for at
             least 1 month before study entry and agree to continue use contraception methods for
             the duration of the study, or if sexually abstinent (not having sexual intercourse)
             and capable of pregnancy, must agree to continue abstinence or to use an acceptable
             method of birth control

          -  Participants must not be a danger to themselves or others, and must have family
             support available to be maintained as out-patients

          -  Participants with a weight of equal to or greater than 29 kilogram

        Exclusion Criteria:

          -  Participants with mild (not serious), moderate (medium level of seriousness), or
             severe (very serious, life threatening) mental retardation

          -  Participants with a known or suspected history of substance dependence (including
             alcohol, but excluding nicotine or caffeine) as per the DSM-IV criteria in the 3
             months before Screening

          -  Participants with a history of certain neurological (pertaining to the nervous system)
             disorders or insulin-dependent diabetes mellitus (disorder in which there is decreased
             insulin in the body or the body's insulin is not effective, resulting in high blood
             sugar, increased thirst and urine, and many other side effects)

          -  Participants who have received a depot injectable antipsychotic within 2 treatment
             cycles before the Screening visit

          -  Participants who have received clozapine in 2 months before the Baseline visit (Day 1
             of Week 1)
Clinical trial NCT00302341 (phase 3, status: terminated)
Conditions: pneumonia, interstitial plasma cell, pneumocystis carinii pneumonia, pneumonia, pneumocystis carinii, hiv infections
ICD codes: Z21
Drugs: pafuramidine maleate (db289), trimethoprim-sulfamethoxazole (tmp-smx)
SMILES: CONC(=N)C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(=N)NOC, CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
Reason stopped: 
    fda clinical hold as of 12/21/07 due to safety concerns
  
Eligibility criteria:

        Inclusion Criteria:

          -  Documented or presumptive HIV infection

          -  Signs and symptoms of PCP present for at least 5 days

          -  Pneumocystis jiroveci confirmed in BAL fluid or induced sputum sample

          -  Suitable candidate for oral therapy

          -  Alveolar-arterial oxygen (A-a) gradient < or = 45 mm Hg on room air and partial
             pressure of oxygen (pO2) > or = 60 mm Hg

          -  No more than 48 hours of prior treatment in the preceding 7 days for PCP treatment at
             full doses; failure of Pneumocystis prophylaxis or use of medications recommended for
             treatment of PCP at doses less than recommended by the CDC Guidelines is acceptable.

        Exclusion Criteria:

          -  Unwilling or unable to discontinue use of other medications with anti-PCP activity

          -  AIDS related cachexia (weight loss that is more than 10% of ideal body weight)

          -  Severe diarrhea and/or vomiting

          -  History of hypersensitivity or severe or life threatening toxicity to TMP-SMX, other
             sulfonamides or pentamidine

          -  Active illicit drug use

          -  Impending respiratory failure or need for intubation

          -  AST and ALT levels > 3 times the upper limit of normal

          -  History of pancreatitis

          -  Severe PCP

          -  Karnofsky score < or = 20

          -  Terminal HIV disease or life expectancy of less than 6 months

          -  Acute concurrent pulmonary pathological condition that would obscure the evaluation of
             response to therapy

          -  Concomitant use of amphotericin B, gangciclovir, cyclosporine, warfarin, thiazide
             diuretics, phenytoin, methotrexate, leucovorin

          -  Receipt of systemic corticosteroids (except replacement therapy) within 14 days of
             study entry at high doses for 3 or more consecutive days. Concomitant use of
             corticosteroids, other than replacement doses for adrenal insufficiency, is also
             excluded unless the patient meets the CDC criteria for use of corticosteroids for
             treatment of PCP

          -  Pregnant or lactating women

          -  The subject has been previously enrolled in the study
Clinical trial NCT01106430 (phase 3, status: completed)
Conditions: attention-deficit/hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: lisdexamfetamine dimesylate, atomoxetine hydrochloride
SMILES: C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN, CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has had an historical or current inadequate response to methylphenidate (MPH)
             treatment. Inadequate response includes but is not limited to the presence of some
             residual symptoms, with associated impairment inadequate duration of action and/or
             variability of symptom control, and/or Investigator feels that the subject may derive
             benefit from an alternative drug treatment to MPH therapy.

          -  Subject is a male or female aged 6-17 years inclusive at the time of consent

          -  Subject must meet Diagnostic and Statistical Manual of Mental Disorders, fourth
             edition. - Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD based on
             a detailed psychiatric evaluation

          -  Subject must have a baseline ADHD-RS-IV total score 28.

        Exclusion Criteria:

          -  Subject has taken more than 1 MPH treatment (for example, 2 or more different MPH
             treatments). Examples include but are not limited to RITALIN immediate release (IR)
             and EQUASYM IR; MEDIKINET IR and CONCERTA; RITALIN long-acting LA and CONCERTA. Note:
             this does not include subjects who have taken IR MPH for dose titration on a
             short-term basis (for example, £4 weeks) with an adequate response

          -  In the Investigator's judgement, subject has failed to respond to more than 1 previous
             course(s) of MPH treatment. Failure to respond includes worsening of symptoms or no
             change/minimal improvement of symptoms.

          -  Subject has previously been exposed to STRATTERA or to amphetamine therapy

          -  Subject has previously demonstrated intolerable side effects to 1 MPH treatment which
             limited titration to acceptable efficacy or that required a decrease in dose resulting
             in unacceptable tolerability and/or efficacy

          -  Subject has a current, controlled (requiring a restricted medication) or uncontrolled,
             comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid
             Axis II disorder or severe Axis I disorder or other symptomatic manifestations, such
             as agitated states, marked anxiety, or tension that, in the opinion of the examining
             physician, will contraindicate treatment with SPD489 or STRATTERA or confound efficacy
             or safety assessments.

          -  Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
Clinical trial NCT01165138 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate/vilanterol inhalation powder, fluticasone furoate inhalation powder, placebo inhaltion powder
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients at least 12 years of age

          -  Male and female; female subjects of childbearing potential must be willing to use
             birth control

          -  Pre-bronchodilator FEV1 of 40-90% predicted normal

          -  Reversibility FEV1 of at least 12% and 200mL

          -  Current asthma therapy includes inhaled corticosteroid use for at least 12 weeks prior
             to first visit

        Exclusion Criteria:

          -  History of life-threatening asthma during last 10 years

          -  Respiratory infection or oral candidiasis

          -  Asthma exacerbation requiring oral corticosteroids or that required overnight
             hospitalisation requiring additional asthma treatment

          -  Uncontrolled disease or clinical abnormality

          -  Allergies to study drugs or the excipients

          -  Taking another investigational medication or prohibited medication

          -  Night shift workers

          -  Current smokers or subjects with a smoking history of at least 10 pack years
Clinical trial NCT00638638 (phase 3, status: unknown status)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: abciximab, abciximab placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients over 18 years of age eligible for randomization in the MICU

          -  Infarct within 6 hours from symptoms onset

          -  Continuous typical chest pain symptoms symptoms for more than 20 min. and-ST segment
             elevation of more than 2 mm in more than two leads (peripheral or precordial)

          -  Signed informed consent form

        Exclusion Criteria:

          -  Ventricular conduction anomalies masking signs of ischemia (left or right bundle
             branch block without evidence of additional elevation), electrical left ventricular
             hypertrophy

          -  Known hypersensitivity to Abciximab or to any component of the product or to murine
             monoclonal antibodies.- Hemorrhagic diathesis, internal hemorrhage

          -  Hemorrhagic stroke within 2 years

          -  Ischemic stroke within the last 3 months- Intra-cranial neoplasm, intracranial
             malformation or arteria

          -  venous aneurysm

          -  Recent intracranial or intraspinal surgery or trauma (within two months)

          -  Recent within (2 months) major surgery- Known peptic ulcer or upper gastrointestinal
             bleeding within the previous 6 month

          -  Known coagulation anomaly

          -  Oral anti-coagulant or low molecular weight heparin treatment- Ongoing thrombolytic
             treatment
Clinical trial NCT00235755 (phase 3, status: completed)
Conditions: seizures
ICD codes: G40.89, R56.1, F44.5, G40.501, G40.509, G40.111, G40.119
Drugs: retigabine, retigabine, placebo
SMILES: CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1, CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or
             without secondary generalization

          -  28-day partial seizure frequency rate of four or more partial seizures over the 8-week
             baseline phase

          -  Currently treated with up to three established AEDs

          -  Vagal Nerve Stimulator may be included

        Exclusion Criteria:

          -  Existing medical or psychiatric condition which could affect patient's health or
             compromise ability to participate in the study

          -  Clinically significant abnormalities on physical exam, vital signs, ECG, or liver
             function tests

          -  Impaired renal function (creatinine clearance less than 50 mL/minute)

          -  Evidence of progressive central nervous disease, lesion, or encephalopathy

          -  History of primary generalized seizures

          -  History of clustering or flurries or status epilepticus within 12 months of study
             entry
Clinical trial NCT01145846 (phase 3, status: unknown status)
Conditions: acute myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cytarabine plus daunorubicin [arm ii (ad regimen)]
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with previously-untreated acute myeloid leukemia (20% or more of blasts in
             bone marrow and/or blood; M6 subtype may have less than 20% of blasts.).
             Therapy-related leukemia or leukemia after myelodysplastic syndrome will be included.

          -  15 years old or older, but 65 years or younger

          -  Adequate performance status (Karnofsky score of 50 or more)

          -  Adequate hepatic and renal function (AST, ALT, bilirubin and creatinine < 2.5 x upper
             normal limit). Elevation of AST or ALT due to hepatic infiltration of leukemic cells
             will be permitted.

          -  Adequate cardiac function (left ventricular ejection fraction of 45% or more on heart
             scan or echocardiogram)

          -  Signed and dated informed consent must be obtained

        Exclusion Criteria:

          -  Patients with acute promyelocytic leukemia or bcr-abl gene rearrangement

          -  Patients with CNS leukemia

          -  Patients with primary granulocytic sarcoma without bone marrow involvement

          -  Prior chemotherapy for leukemia or anthracycline treatment for any malignancy.
             Hydroxyurea for reduction of leukemic cell burden before induction chemotherapy will
             be permitted.

          -  Presence of significant active infection

          -  Presence of uncontrolled bleeding

          -  Significant cardiovascular disease including myocardial infarction within previous 6
             months

          -  Any coexisting major illness or organ failure

          -  Patients with psychiatric disorder or mental deficiency severe as to make compliance
             with the treatment unlike, and making informed consent impossible

          -  Nursing women, pregnant women, women of childbearing potential who do not want
             adequate contraception

          -  Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years
             following therapy with curative intent (except curatively treated nonmelanoma skin
             cancer, in situ carcinoma, or cervical intraepithelial neoplasia)
Clinical trial NCT00605267 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: tamoxifen, anastrazole (arimidex), goserelin acetate (zoladex)
SMILES: OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable
             and measurable breast cancer who have provided written informed consent

        Exclusion Criteria:

          -  Medical history of chemotherapy or endocrine therapy for breast cancer, or with
             treatment history of radiotherapy. Unwillingness to stop taking any drug known to
             affect sex hormone status (including hormone replacement therapy (HRT).
Clinical trial NCT00450658 (phase 3, status: completed)
Conditions: peptic ulcer
ICD codes: P78.82, Z87.11, K27.0, K27.1, K27.3, K27.4, K27.5
Drugs: hzt-501, ibuprofen
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Expected to require daily administration of a nonsteroidal anti-inflammatory drug
             (NSAID) for at least the coming six months for conditions such as osteoarthritis,
             rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and
             chronic soft tissue pain.

          -  Did not use a NSAID within the 30 days prior to study entry

        Exclusion Criteria:

          -  History of erosive esophagitis

          -  History of any of the following serious gastrointestinal complications:

               -  perforation of ulcers,

               -  gastric outlet obstruction due to ulcers,

               -  gastrointestinal bleeding.

          -  Active cardiac, renal, and/or hepatic disease

          -  Current Helicobacter pylori (H. pylori) infection

          -  Use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin
             within the 14 days prior to study entry.

          -  Uncontrolled diabetes

          -  Uncontrolled hypertension

          -  Positive pregnancy test at screening

          -  Positive test at Screening for human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C.

          -  Currently participating, or participation within 30 days prior to study entry, in an
             investigational drug study

        Please note that there are other additional criteria. The study center will determine if
        patients meet all of the criteria.
Clinical trial NCT00296309 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: tacrolimus
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with minimum 60 years of age and end stage kidney disease who are suitable
             candidates for primary renal transplantation or retransplantation are eligible for the
             study. Patients receiving a kidney transplant, from a cadaveric or living donor (not
             HLA identical) with compatible ABO blood type can be included.

        Exclusion Criteria:

          -  Patient has an immunological high risk

          -  Cold ischemia time greater than 30 hours.

          -  Patient has significant liver disease

          -  Patient is allergic or intolerant to study medication

          -  Patient or donor is known to be HIV positive.

          -  Patient with malignancy or history of malignancy

          -  Patient has significant, uncontrolled concomitant infections
Clinical trial NCT00198120 (phase 3, status: completed)
Conditions: autistic disorder
ICD codes: F84.0
Drugs: d-cycloserine, placebo
SMILES: N[C@@H]1CONC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 3 Years to 12 Years

          -  Diagnostic Statistical Manual Version -IV (DSM-IV) and Autism Diagnostic Interview -
             Revised (ADI-R)-confirmed Diagnosis of Autistic Disorder

          -  Aberrant Behavior Checklist (ABC) Lethargy Subscale Score of 13 or greater

        Exclusion Criteria:

          -  Children with Severe to Profound Mental Retardation

          -  Weight at Screening Visit <11 kilograms

          -  Clinical Global Impressions-Severity Score of 7

          -  Presence of a Neurodevelopmental Disorder with Possible Associations to Autism:
             Subjects with Fragile X Syndrome, Tuberous Sclerosis, or other neurodevelopmental
             disorders known to be associated with autism or autistic features will be excluded.

          -  Presence of a Psychiatric Disorder that would Require a Specific Type of Treatment:
             Subjects with major depressive disorder, bipolar disorder, or a psychotic disorder
             will be excluded because treatment for these disorders often requires specific
             psychotropic agents. Subjects with an active substance use disorder will be excluded
             because of safety concerns and problems this would cause in assessing efficacy.

          -  Presence of a Medical Condition that would make Treatment with D-Cycloserine Less
             Safe: Subjects with significant cardiac, hepatic, or renal disease will be excluded
             due to concerns about pharmacokinetic alterations or adverse effects. Subjects with
             epilepsy or a history of seizures will be excluded due to rare reports of seizures
             with high doses of D-cycloserine. D-cycloserine is an U.S. FDA Pregnancy Category C
             drug. Because of the unknown effects of D-cycloserine on the developing human fetus,
             females of childbearing potential will be given a urine pregnancy test and required to
             use a suitable form of birth control during the study.
Clinical trial NCT00535782 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tocilizumab, placebo, methotrexate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age

          -  rheumatoid arthritis (RA) of >6 months duration

          -  able to receive outpatient treatment

          -  on methotrexate for at least 12 weeks before entering study, at a stable dose of
             7.5-25 mg/week for the last 8 weeks

          -  oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) permitted, if
             at a stable dose for 4 weeks before study start

        Exclusion Criteria

          -  major surgery (including joint surgery) within 8 weeks prior to screening, or planned
             surgery within 6 months after entering study

          -  history of, or current inflammatory joint disease or rheumatic autoimmune disease
             other than RA

          -  inadequate response to anti-tumor necrosis factor (TNF) agent during the 6 months
             prior to baseline, or inadequate response to >2 anti-TNF agents

          -  initiation of treatment with lipid lowering agents within 12 weeks prior to baseline
Clinical trial NCT00449956 (phase 3, status: completed)
Conditions: glaucoma
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821
Drugs: dorzolamide hydrochloride (+) timolol maleate, comparator: timolol maleate, comparator: dorzolamide hydrochloride
SMILES: CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with glaucoma and ocular hypertension

        Exclusion Criteria:

          -  History of ocular surgery within 3 months

          -  Administration contradiction to timolol and dorzolamide